Pharma & Healthcare
Global PCSK9 Inhibitors Market Research Report 2025
- Sep 09, 25
- ID: 496384
- Pages: 91
- Figures: 89
- Views: 4
Report Scope
This report aims to provide a comprehensive presentation of the global market for PCSK9 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PCSK9 Inhibitors.
The PCSK9 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PCSK9 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PCSK9 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Amgen
Eli Lilly
Sanofi
Pfizer
Novartis
Roche
Merck
Alnylam
AstraZeneca
Affiris
BMS
Ionis Pharmaceuticals
Cyon Therapeutics
Daiichi Sankyo
Segment by Type
Epatha(Evolocumab)
Praluent(Alirocumab)
Bococizumab
Others
Segment by Application
Clinical Application
Drug Development
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PCSK9 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PCSK9 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report aims to provide a comprehensive presentation of the global market for PCSK9 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PCSK9 Inhibitors.
The PCSK9 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PCSK9 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PCSK9 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Amgen
Eli Lilly
Sanofi
Pfizer
Novartis
Roche
Merck
Alnylam
AstraZeneca
Affiris
BMS
Ionis Pharmaceuticals
Cyon Therapeutics
Daiichi Sankyo
Segment by Type
Epatha(Evolocumab)
Praluent(Alirocumab)
Bococizumab
Others
Segment by Application
Clinical Application
Drug Development
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PCSK9 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PCSK9 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 PCSK9 Inhibitors Market Overview
1.1 Product Definition
1.2 PCSK9 Inhibitors by Type
1.2.1 Global PCSK9 Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Epatha(Evolocumab)
1.2.3 Praluent(Alirocumab)
1.2.4 Bococizumab
1.2.5 Others
1.3 PCSK9 Inhibitors by Application
1.3.1 Global PCSK9 Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Clinical Application
1.3.3 Drug Development
1.3.4 Other
1.4 Global PCSK9 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PCSK9 Inhibitors Revenue 2020-2031
1.4.2 Global PCSK9 Inhibitors Sales 2020-2031
1.4.3 Global PCSK9 Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PCSK9 Inhibitors Market Competition by Manufacturers
2.1 Global PCSK9 Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global PCSK9 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PCSK9 Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PCSK9 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PCSK9 Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of PCSK9 Inhibitors, Date of Enter into This Industry
2.8 Global PCSK9 Inhibitors Market Competitive Situation and Trends
2.8.1 Global PCSK9 Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PCSK9 Inhibitors Players Market Share by Revenue
2.8.3 Global PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PCSK9 Inhibitors Market Scenario by Region
3.1 Global PCSK9 Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PCSK9 Inhibitors Sales by Region: 2020-2031
3.2.1 Global PCSK9 Inhibitors Sales by Region: 2020-2025
3.2.2 Global PCSK9 Inhibitors Sales by Region: 2026-2031
3.3 Global PCSK9 Inhibitors Revenue by Region: 2020-2031
3.3.1 Global PCSK9 Inhibitors Revenue by Region: 2020-2025
3.3.2 Global PCSK9 Inhibitors Revenue by Region: 2026-2031
3.4 North America PCSK9 Inhibitors Market Facts & Figures by Country
3.4.1 North America PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PCSK9 Inhibitors Sales by Country (2020-2031)
3.4.3 North America PCSK9 Inhibitors Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PCSK9 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PCSK9 Inhibitors Sales by Country (2020-2031)
3.5.3 Europe PCSK9 Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PCSK9 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific PCSK9 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PCSK9 Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific PCSK9 Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PCSK9 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PCSK9 Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America PCSK9 Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PCSK9 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PCSK9 Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa PCSK9 Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global PCSK9 Inhibitors Sales by Type (2020-2031)
4.1.1 Global PCSK9 Inhibitors Sales by Type (2020-2025)
4.1.2 Global PCSK9 Inhibitors Sales by Type (2026-2031)
4.1.3 Global PCSK9 Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global PCSK9 Inhibitors Revenue by Type (2020-2031)
4.2.1 Global PCSK9 Inhibitors Revenue by Type (2020-2025)
4.2.2 Global PCSK9 Inhibitors Revenue by Type (2026-2031)
4.2.3 Global PCSK9 Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global PCSK9 Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global PCSK9 Inhibitors Sales by Application (2020-2031)
5.1.1 Global PCSK9 Inhibitors Sales by Application (2020-2025)
5.1.2 Global PCSK9 Inhibitors Sales by Application (2026-2031)
5.1.3 Global PCSK9 Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global PCSK9 Inhibitors Revenue by Application (2020-2031)
5.2.1 Global PCSK9 Inhibitors Revenue by Application (2020-2025)
5.2.2 Global PCSK9 Inhibitors Revenue by Application (2026-2031)
5.2.3 Global PCSK9 Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global PCSK9 Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amgen PCSK9 Inhibitors Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly PCSK9 Inhibitors Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi PCSK9 Inhibitors Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer PCSK9 Inhibitors Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis PCSK9 Inhibitors Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Roche
6.6.1 Roche Company Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Roche PCSK9 Inhibitors Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Merck PCSK9 Inhibitors Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Alnylam
6.8.1 Alnylam Company Information
6.8.2 Alnylam Description and Business Overview
6.8.3 Alnylam PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alnylam PCSK9 Inhibitors Product Portfolio
6.8.5 Alnylam Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Company Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 AstraZeneca PCSK9 Inhibitors Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Affiris
6.10.1 Affiris Company Information
6.10.2 Affiris Description and Business Overview
6.10.3 Affiris PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Affiris PCSK9 Inhibitors Product Portfolio
6.10.5 Affiris Recent Developments/Updates
6.11 BMS
6.11.1 BMS Company Information
6.11.2 BMS Description and Business Overview
6.11.3 BMS PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 BMS PCSK9 Inhibitors Product Portfolio
6.11.5 BMS Recent Developments/Updates
6.12 Ionis Pharmaceuticals
6.12.1 Ionis Pharmaceuticals Company Information
6.12.2 Ionis Pharmaceuticals Description and Business Overview
6.12.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio
6.12.5 Ionis Pharmaceuticals Recent Developments/Updates
6.13 Cyon Therapeutics
6.13.1 Cyon Therapeutics Company Information
6.13.2 Cyon Therapeutics Description and Business Overview
6.13.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Cyon Therapeutics PCSK9 Inhibitors Product Portfolio
6.13.5 Cyon Therapeutics Recent Developments/Updates
6.14 Daiichi Sankyo
6.14.1 Daiichi Sankyo Company Information
6.14.2 Daiichi Sankyo Description and Business Overview
6.14.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Daiichi Sankyo PCSK9 Inhibitors Product Portfolio
6.14.5 Daiichi Sankyo Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PCSK9 Inhibitors Industry Chain Analysis
7.2 PCSK9 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PCSK9 Inhibitors Production Mode & Process Analysis
7.4 PCSK9 Inhibitors Sales and Marketing
7.4.1 PCSK9 Inhibitors Sales Channels
7.4.2 PCSK9 Inhibitors Distributors
7.5 PCSK9 Inhibitors Customer Analysis
8 PCSK9 Inhibitors Market Dynamics
8.1 PCSK9 Inhibitors Industry Trends
8.2 PCSK9 Inhibitors Market Drivers
8.3 PCSK9 Inhibitors Market Challenges
8.4 PCSK9 Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 PCSK9 Inhibitors by Type
1.2.1 Global PCSK9 Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Epatha(Evolocumab)
1.2.3 Praluent(Alirocumab)
1.2.4 Bococizumab
1.2.5 Others
1.3 PCSK9 Inhibitors by Application
1.3.1 Global PCSK9 Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Clinical Application
1.3.3 Drug Development
1.3.4 Other
1.4 Global PCSK9 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PCSK9 Inhibitors Revenue 2020-2031
1.4.2 Global PCSK9 Inhibitors Sales 2020-2031
1.4.3 Global PCSK9 Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PCSK9 Inhibitors Market Competition by Manufacturers
2.1 Global PCSK9 Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global PCSK9 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PCSK9 Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PCSK9 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PCSK9 Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of PCSK9 Inhibitors, Date of Enter into This Industry
2.8 Global PCSK9 Inhibitors Market Competitive Situation and Trends
2.8.1 Global PCSK9 Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PCSK9 Inhibitors Players Market Share by Revenue
2.8.3 Global PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PCSK9 Inhibitors Market Scenario by Region
3.1 Global PCSK9 Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PCSK9 Inhibitors Sales by Region: 2020-2031
3.2.1 Global PCSK9 Inhibitors Sales by Region: 2020-2025
3.2.2 Global PCSK9 Inhibitors Sales by Region: 2026-2031
3.3 Global PCSK9 Inhibitors Revenue by Region: 2020-2031
3.3.1 Global PCSK9 Inhibitors Revenue by Region: 2020-2025
3.3.2 Global PCSK9 Inhibitors Revenue by Region: 2026-2031
3.4 North America PCSK9 Inhibitors Market Facts & Figures by Country
3.4.1 North America PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PCSK9 Inhibitors Sales by Country (2020-2031)
3.4.3 North America PCSK9 Inhibitors Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PCSK9 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PCSK9 Inhibitors Sales by Country (2020-2031)
3.5.3 Europe PCSK9 Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PCSK9 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific PCSK9 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PCSK9 Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific PCSK9 Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PCSK9 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PCSK9 Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America PCSK9 Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PCSK9 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PCSK9 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PCSK9 Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa PCSK9 Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global PCSK9 Inhibitors Sales by Type (2020-2031)
4.1.1 Global PCSK9 Inhibitors Sales by Type (2020-2025)
4.1.2 Global PCSK9 Inhibitors Sales by Type (2026-2031)
4.1.3 Global PCSK9 Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global PCSK9 Inhibitors Revenue by Type (2020-2031)
4.2.1 Global PCSK9 Inhibitors Revenue by Type (2020-2025)
4.2.2 Global PCSK9 Inhibitors Revenue by Type (2026-2031)
4.2.3 Global PCSK9 Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global PCSK9 Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global PCSK9 Inhibitors Sales by Application (2020-2031)
5.1.1 Global PCSK9 Inhibitors Sales by Application (2020-2025)
5.1.2 Global PCSK9 Inhibitors Sales by Application (2026-2031)
5.1.3 Global PCSK9 Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global PCSK9 Inhibitors Revenue by Application (2020-2031)
5.2.1 Global PCSK9 Inhibitors Revenue by Application (2020-2025)
5.2.2 Global PCSK9 Inhibitors Revenue by Application (2026-2031)
5.2.3 Global PCSK9 Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global PCSK9 Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amgen PCSK9 Inhibitors Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly PCSK9 Inhibitors Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi PCSK9 Inhibitors Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer PCSK9 Inhibitors Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis PCSK9 Inhibitors Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Roche
6.6.1 Roche Company Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Roche PCSK9 Inhibitors Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Merck
6.7.1 Merck Company Information
6.7.2 Merck Description and Business Overview
6.7.3 Merck PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Merck PCSK9 Inhibitors Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Alnylam
6.8.1 Alnylam Company Information
6.8.2 Alnylam Description and Business Overview
6.8.3 Alnylam PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alnylam PCSK9 Inhibitors Product Portfolio
6.8.5 Alnylam Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Company Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 AstraZeneca PCSK9 Inhibitors Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Affiris
6.10.1 Affiris Company Information
6.10.2 Affiris Description and Business Overview
6.10.3 Affiris PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Affiris PCSK9 Inhibitors Product Portfolio
6.10.5 Affiris Recent Developments/Updates
6.11 BMS
6.11.1 BMS Company Information
6.11.2 BMS Description and Business Overview
6.11.3 BMS PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 BMS PCSK9 Inhibitors Product Portfolio
6.11.5 BMS Recent Developments/Updates
6.12 Ionis Pharmaceuticals
6.12.1 Ionis Pharmaceuticals Company Information
6.12.2 Ionis Pharmaceuticals Description and Business Overview
6.12.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio
6.12.5 Ionis Pharmaceuticals Recent Developments/Updates
6.13 Cyon Therapeutics
6.13.1 Cyon Therapeutics Company Information
6.13.2 Cyon Therapeutics Description and Business Overview
6.13.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Cyon Therapeutics PCSK9 Inhibitors Product Portfolio
6.13.5 Cyon Therapeutics Recent Developments/Updates
6.14 Daiichi Sankyo
6.14.1 Daiichi Sankyo Company Information
6.14.2 Daiichi Sankyo Description and Business Overview
6.14.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Daiichi Sankyo PCSK9 Inhibitors Product Portfolio
6.14.5 Daiichi Sankyo Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PCSK9 Inhibitors Industry Chain Analysis
7.2 PCSK9 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PCSK9 Inhibitors Production Mode & Process Analysis
7.4 PCSK9 Inhibitors Sales and Marketing
7.4.1 PCSK9 Inhibitors Sales Channels
7.4.2 PCSK9 Inhibitors Distributors
7.5 PCSK9 Inhibitors Customer Analysis
8 PCSK9 Inhibitors Market Dynamics
8.1 PCSK9 Inhibitors Industry Trends
8.2 PCSK9 Inhibitors Market Drivers
8.3 PCSK9 Inhibitors Market Challenges
8.4 PCSK9 Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global PCSK9 Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global PCSK9 Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global PCSK9 Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global PCSK9 Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global PCSK9 Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global PCSK9 Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global PCSK9 Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market PCSK9 Inhibitors Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of PCSK9 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PCSK9 Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of PCSK9 Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PCSK9 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PCSK9 Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global PCSK9 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 18. Global PCSK9 Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global PCSK9 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 20. Global PCSK9 Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global PCSK9 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global PCSK9 Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global PCSK9 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global PCSK9 Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 27. North America PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 28. North America PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 32. Europe PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 33. Europe PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific PCSK9 Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific PCSK9 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific PCSK9 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific PCSK9 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific PCSK9 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 42. Latin America PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 43. Latin America PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global PCSK9 Inhibitors Sales (K Units) by Type (2020-2025)
Table 51. Global PCSK9 Inhibitors Sales (K Units) by Type (2026-2031)
Table 52. Global PCSK9 Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global PCSK9 Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global PCSK9 Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global PCSK9 Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global PCSK9 Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global PCSK9 Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2020-2025)
Table 59. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2026-2031)
Table 60. Global PCSK9 Inhibitors Sales (K Units) by Application (2020-2025)
Table 61. Global PCSK9 Inhibitors Sales (K Units) by Application (2026-2031)
Table 62. Global PCSK9 Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global PCSK9 Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global PCSK9 Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global PCSK9 Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global PCSK9 Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global PCSK9 Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2020-2025)
Table 69. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2026-2031)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Amgen PCSK9 Inhibitors Product
Table 74. Amgen Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Eli Lilly PCSK9 Inhibitors Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Sanofi PCSK9 Inhibitors Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Pfizer PCSK9 Inhibitors Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Novartis PCSK9 Inhibitors Product
Table 94. Novartis Recent Developments/Updates
Table 95. Roche Company Information
Table 96. Roche Description and Business Overview
Table 97. Roche PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Roche PCSK9 Inhibitors Product
Table 99. Roche Recent Developments/Updates
Table 100. Merck Company Information
Table 101. Merck Description and Business Overview
Table 102. Merck PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Merck PCSK9 Inhibitors Product
Table 104. Merck Recent Developments/Updates
Table 105. Alnylam Company Information
Table 106. Alnylam Description and Business Overview
Table 107. Alnylam PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Alnylam PCSK9 Inhibitors Product
Table 109. Alnylam Recent Developments/Updates
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. AstraZeneca PCSK9 Inhibitors Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Affiris Company Information
Table 116. Affiris Description and Business Overview
Table 117. Affiris PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Affiris PCSK9 Inhibitors Product
Table 119. Affiris Recent Developments/Updates
Table 120. BMS Company Information
Table 121. BMS Description and Business Overview
Table 122. BMS PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. BMS PCSK9 Inhibitors Product
Table 124. BMS Recent Developments/Updates
Table 125. Ionis Pharmaceuticals Company Information
Table 126. Ionis Pharmaceuticals Description and Business Overview
Table 127. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Ionis Pharmaceuticals PCSK9 Inhibitors Product
Table 129. Ionis Pharmaceuticals Recent Developments/Updates
Table 130. Cyon Therapeutics Company Information
Table 131. Cyon Therapeutics Description and Business Overview
Table 132. Cyon Therapeutics PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Cyon Therapeutics PCSK9 Inhibitors Product
Table 134. Cyon Therapeutics Recent Developments/Updates
Table 135. Daiichi Sankyo Company Information
Table 136. Daiichi Sankyo Description and Business Overview
Table 137. Daiichi Sankyo PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Daiichi Sankyo PCSK9 Inhibitors Product
Table 139. Daiichi Sankyo Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. PCSK9 Inhibitors Distributors List
Table 143. PCSK9 Inhibitors Customers List
Table 144. PCSK9 Inhibitors Market Trends
Table 145. PCSK9 Inhibitors Market Drivers
Table 146. PCSK9 Inhibitors Market Challenges
Table 147. PCSK9 Inhibitors Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of PCSK9 Inhibitors
Figure 2. Global PCSK9 Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global PCSK9 Inhibitors Market Share by Type: 2024 & 2031
Figure 4. Epatha(Evolocumab) Product Picture
Figure 5. Praluent(Alirocumab) Product Picture
Figure 6. Bococizumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global PCSK9 Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global PCSK9 Inhibitors Market Share by Application: 2024 & 2031
Figure 10. Clinical Application
Figure 11. Drug Development
Figure 12. Other
Figure 13. Global PCSK9 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global PCSK9 Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 15. Global PCSK9 Inhibitors Sales (2020-2031) & (K Units)
Figure 16. Global PCSK9 Inhibitors Average Price (USD/Unit) & (2020-2031)
Figure 17. PCSK9 Inhibitors Report Years Considered
Figure 18. PCSK9 Inhibitors Sales Share by Manufacturers in 2024
Figure 19. Global PCSK9 Inhibitors Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest PCSK9 Inhibitors Players: Market Share by Revenue in PCSK9 Inhibitors in 2024
Figure 21. PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 24. North America PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 25. U.S. PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 28. Europe PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 29. Germany PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific PCSK9 Inhibitors Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific PCSK9 Inhibitors Revenue Market Share by Region (2020-2031)
Figure 36. China PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Taiwan PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Indonesia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Thailand PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Malaysia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Philippines PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 47. Latin America PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 48. Mexico PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 53. Turkey PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. U.A.E PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of PCSK9 Inhibitors by Type (2020-2031)
Figure 57. Global Revenue Market Share of PCSK9 Inhibitors by Type (2020-2031)
Figure 58. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2020-2031)
Figure 59. Global Sales Market Share of PCSK9 Inhibitors by Application (2020-2031)
Figure 60. Global Revenue Market Share of PCSK9 Inhibitors by Application (2020-2031)
Figure 61. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2020-2031)
Figure 62. PCSK9 Inhibitors Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global PCSK9 Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global PCSK9 Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global PCSK9 Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global PCSK9 Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global PCSK9 Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global PCSK9 Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global PCSK9 Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market PCSK9 Inhibitors Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of PCSK9 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of PCSK9 Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PCSK9 Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of PCSK9 Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PCSK9 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PCSK9 Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global PCSK9 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 18. Global PCSK9 Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global PCSK9 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 20. Global PCSK9 Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global PCSK9 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global PCSK9 Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global PCSK9 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global PCSK9 Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 27. North America PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 28. North America PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 32. Europe PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 33. Europe PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific PCSK9 Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific PCSK9 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific PCSK9 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific PCSK9 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific PCSK9 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 42. Latin America PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 43. Latin America PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa PCSK9 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa PCSK9 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa PCSK9 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global PCSK9 Inhibitors Sales (K Units) by Type (2020-2025)
Table 51. Global PCSK9 Inhibitors Sales (K Units) by Type (2026-2031)
Table 52. Global PCSK9 Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global PCSK9 Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global PCSK9 Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global PCSK9 Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global PCSK9 Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global PCSK9 Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2020-2025)
Table 59. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2026-2031)
Table 60. Global PCSK9 Inhibitors Sales (K Units) by Application (2020-2025)
Table 61. Global PCSK9 Inhibitors Sales (K Units) by Application (2026-2031)
Table 62. Global PCSK9 Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global PCSK9 Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global PCSK9 Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global PCSK9 Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global PCSK9 Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global PCSK9 Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2020-2025)
Table 69. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2026-2031)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Amgen PCSK9 Inhibitors Product
Table 74. Amgen Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Eli Lilly PCSK9 Inhibitors Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Sanofi Company Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Sanofi PCSK9 Inhibitors Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Pfizer PCSK9 Inhibitors Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Novartis PCSK9 Inhibitors Product
Table 94. Novartis Recent Developments/Updates
Table 95. Roche Company Information
Table 96. Roche Description and Business Overview
Table 97. Roche PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Roche PCSK9 Inhibitors Product
Table 99. Roche Recent Developments/Updates
Table 100. Merck Company Information
Table 101. Merck Description and Business Overview
Table 102. Merck PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Merck PCSK9 Inhibitors Product
Table 104. Merck Recent Developments/Updates
Table 105. Alnylam Company Information
Table 106. Alnylam Description and Business Overview
Table 107. Alnylam PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Alnylam PCSK9 Inhibitors Product
Table 109. Alnylam Recent Developments/Updates
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. AstraZeneca PCSK9 Inhibitors Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Affiris Company Information
Table 116. Affiris Description and Business Overview
Table 117. Affiris PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Affiris PCSK9 Inhibitors Product
Table 119. Affiris Recent Developments/Updates
Table 120. BMS Company Information
Table 121. BMS Description and Business Overview
Table 122. BMS PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. BMS PCSK9 Inhibitors Product
Table 124. BMS Recent Developments/Updates
Table 125. Ionis Pharmaceuticals Company Information
Table 126. Ionis Pharmaceuticals Description and Business Overview
Table 127. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. Ionis Pharmaceuticals PCSK9 Inhibitors Product
Table 129. Ionis Pharmaceuticals Recent Developments/Updates
Table 130. Cyon Therapeutics Company Information
Table 131. Cyon Therapeutics Description and Business Overview
Table 132. Cyon Therapeutics PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Cyon Therapeutics PCSK9 Inhibitors Product
Table 134. Cyon Therapeutics Recent Developments/Updates
Table 135. Daiichi Sankyo Company Information
Table 136. Daiichi Sankyo Description and Business Overview
Table 137. Daiichi Sankyo PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 138. Daiichi Sankyo PCSK9 Inhibitors Product
Table 139. Daiichi Sankyo Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. PCSK9 Inhibitors Distributors List
Table 143. PCSK9 Inhibitors Customers List
Table 144. PCSK9 Inhibitors Market Trends
Table 145. PCSK9 Inhibitors Market Drivers
Table 146. PCSK9 Inhibitors Market Challenges
Table 147. PCSK9 Inhibitors Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of PCSK9 Inhibitors
Figure 2. Global PCSK9 Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global PCSK9 Inhibitors Market Share by Type: 2024 & 2031
Figure 4. Epatha(Evolocumab) Product Picture
Figure 5. Praluent(Alirocumab) Product Picture
Figure 6. Bococizumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global PCSK9 Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global PCSK9 Inhibitors Market Share by Application: 2024 & 2031
Figure 10. Clinical Application
Figure 11. Drug Development
Figure 12. Other
Figure 13. Global PCSK9 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global PCSK9 Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 15. Global PCSK9 Inhibitors Sales (2020-2031) & (K Units)
Figure 16. Global PCSK9 Inhibitors Average Price (USD/Unit) & (2020-2031)
Figure 17. PCSK9 Inhibitors Report Years Considered
Figure 18. PCSK9 Inhibitors Sales Share by Manufacturers in 2024
Figure 19. Global PCSK9 Inhibitors Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest PCSK9 Inhibitors Players: Market Share by Revenue in PCSK9 Inhibitors in 2024
Figure 21. PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global PCSK9 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 24. North America PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 25. U.S. PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 28. Europe PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 29. Germany PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific PCSK9 Inhibitors Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific PCSK9 Inhibitors Revenue Market Share by Region (2020-2031)
Figure 36. China PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Taiwan PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Indonesia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Thailand PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Malaysia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Philippines PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 47. Latin America PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 48. Mexico PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa PCSK9 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 53. Turkey PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. U.A.E PCSK9 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of PCSK9 Inhibitors by Type (2020-2031)
Figure 57. Global Revenue Market Share of PCSK9 Inhibitors by Type (2020-2031)
Figure 58. Global PCSK9 Inhibitors Price (USD/Unit) by Type (2020-2031)
Figure 59. Global Sales Market Share of PCSK9 Inhibitors by Application (2020-2031)
Figure 60. Global Revenue Market Share of PCSK9 Inhibitors by Application (2020-2031)
Figure 61. Global PCSK9 Inhibitors Price (USD/Unit) by Application (2020-2031)
Figure 62. PCSK9 Inhibitors Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232